Page R L, Ruscin J M, Fish D, Lapointe M
Department of Pharmacy Practice, School of Pharmacy University of Colorado Health Sciences Center, Denver 80262, USA.
Pharmacotherapy. 2001 Nov;21(11):1436-43. doi: 10.1592/phco.21.17.1436.34434.
A 42-year-old man who had received a cadaveric kidney transplant 9 years earlier was admitted to the hospital with pneumonia. His oral cyclosporine dosage for the past 2 years was stabilized at 100 mg twice/day; his cyclosporine whole blood trough levels 15 days earlier and on the day he was admitted were both 178 ng/ml. The patient was treated with intravenous ceftriaxone and intravenous azithromycin and continued to receive the same dosage of oral cyclosporine. On hospital day 3, his cyclosporine trough level rose to 400 ng/ml and his dosage was reduced by 50%. Trough levels were 181 ng/ml and 175 ng/ml on hospital days 6 and 9, respectively On hospital day 9, the patient stopped receiving azithromycin. On hospital day 14, his cyclosporine trough level dropped to 76 ng/ml, and his cyclosporine dosage was increased back to 100 mg twice/day. The dosage produced trough levels consistent with those before he had been admitted. The patient was discharged on day 20, and a follow-up cyclosporine trough level determined 3 weeks later was 175 ng/ml. Administration of azithromycin may have caused the increased cyclosporine concentrations in this patient through p-glycoprotein inhibition and/or competition for biliary excretion. Azithromycin's interference may be inferred by the increase in cyclosporine levels after administration of this drug and the decrease in cyclosporine levels after its discontinuation-both consistent with the pharmacokinetic properties of cyclosporine. Ceftriaxone and acute-phase reactant activation during infection, however, also may have interfered with the patient's cyclosporine elimination. Azithromycin generally is considered unlikely to interact with cyclosporine. Nonetheless, practitioners should be aware of this possibility and should monitor cyclosporine levels closely, especially in critically ill patients who have other complications.
一名9年前接受尸体肾移植的42岁男性因肺炎入院。过去2年他口服环孢素的剂量稳定在每日两次,每次100毫克;入院前15天及入院当天他的环孢素全血谷浓度均为178纳克/毫升。患者接受了静脉注射头孢曲松和静脉注射阿奇霉素治疗,并继续服用相同剂量的口服环孢素。住院第3天,他的环孢素谷浓度升至400纳克/毫升,剂量减少了50%。住院第6天和第9天的谷浓度分别为181纳克/毫升和175纳克/毫升。住院第9天,患者停止服用阿奇霉素。住院第14天,他的环孢素谷浓度降至76纳克/毫升,环孢素剂量增加回每日两次,每次100毫克。该剂量产生的谷浓度与入院前一致。患者于第20天出院,3周后测定的环孢素谷浓度随访值为175纳克/毫升。阿奇霉素的使用可能通过抑制P-糖蛋白和/或竞争胆汁排泄导致该患者环孢素浓度升高。阿奇霉素的干扰可通过用药后环孢素水平升高以及停药后环孢素水平降低来推断——这两者均与环孢素的药代动力学特性相符。然而,头孢曲松以及感染期间急性期反应物的激活也可能干扰了患者的环孢素清除。一般认为阿奇霉素不太可能与环孢素相互作用。尽管如此,从业者应意识到这种可能性,并应密切监测环孢素水平,尤其是在有其他并发症的重症患者中。